HC Wainwright Reduces Earnings Estimates for UroGen Pharma

UroGen Pharma Ltd. (NASDAQ:URGN) – Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of UroGen Pharma in a research note issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.93) per share for the quarter, down from their prior estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.27) EPS and FY2026 earnings at $0.29 EPS.

A number of other equities analysts have also recently issued reports on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $10.82 on Thursday. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70. The stock has a market cap of $253.77 million, a price-to-earnings ratio of -3.43 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a fifty day moving average of $10.45 and a 200-day moving average of $11.70.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million.

Insider Activity

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma during the fourth quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of UroGen Pharma in the fourth quarter valued at approximately $67,000. Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the fourth quarter valued at approximately $101,000. BNP Paribas Financial Markets increased its position in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma during the 4th quarter valued at approximately $126,000. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.